Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Forest Laboratories history
Forest Laboratories company history timeline
Forest Laboratories was founded in 1956 as a small laboratory service company.
He found evidence to support the allegations, Lowey resigned, and Solomon took over as CEO of the company in 1977.
1984: Forest significantly boosts its sales force with the purchase of O'Neal, Jones & Feldman Inc.
1986: Company purchases Aerobid, an antiasthma drug.
Aerobid, along with Forest's other two major drugs (Tessalon, a cough medication, and Propranolol, a generic used to treat high blood pressure), would account for over 40 percent of the company's sales by 1993.
Forest reached a peak in fiscal 1996 when record revenues of $461.8 million were recorded.
For Forest, however, Cipramil was a perfect fit, and so Solomon signed a deal with Lundbeck in early 1996 to license the drug for sale in the United States under the name Celexa.
An NDA for Aerospan was filed with the FDA in April 2000. As a result of a March 1997 ruling by the FDA, Forest was facing the withdrawal of approval for Aerobid because it, like most other asthma inhalers, contained chlorofluorocarbons (CFCs), which were being phased out of use because of the harm they were doing to the environment.
A minor success for Forest came in October 1999 when Infasurf was launched.
In 1999 the stock began trading on the prestigious New York Stock Exchange, having been listed for three decades on the American Stock Exchange.
Rate how well Forest Laboratories lives up to its initial vision.
Forest Laboratories jobs
Do you work at Forest Laboratories?
Does Forest Laboratories communicate its history to new hires?
Forest Laboratories competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | 1891 | $64.2B | 74,000 | 1,305 |
| Johnson & Johnson | 1886 | $88.8B | 134,500 | 1,447 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 275 |
| Salix Pharmaceuticals | 1989 | $1.1B | 1,000 | - |
| Amgen | 1980 | $33.4B | 22,000 | 569 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 678 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Seagen | 1997 | $2.0B | 900 | - |
| Regeneron | 1988 | $14.2B | 9,123 | 338 |
| Otsuka Pharmaceuticals | 1989 | $4.4B | 7,500 | 2,946 |
Forest Laboratories history FAQs
Zippia gives an in-depth look into the details of Forest Laboratories, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Forest Laboratories. The employee data is based on information from people who have self-reported their past or current employments at Forest Laboratories. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Forest Laboratories. The data presented on this page does not represent the view of Forest Laboratories and its employees or that of Zippia.
Forest Laboratories may also be known as or be related to FOREST LABORATORIES INC, Forest Laboratories and Forest Laboratories LLC.